LUBT-017

LUBT-017 is a **proposed aflibercept biosimilar** being developed by Lupin for ophthalmic use, particularly retinal vascular diseases. Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for **vascular endothelial growth factor A**, **vascular endothelial growth factor B**, and **placental growth factor**, thereby suppressing pathological angiogenesis and vascular permeability in the retina. Publicly available evidence identifies LUBT-017 specifically as an aflibercept biosimilar candidate rather than a distinct new molecular entity; however, detailed public information on its exact formulation, clinical status, route, dosage form, and manufacturer is limited.

Other names

aflibercept biosimilar